RDD-1609 is under clinical development by 9 Meters Biopharma and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect RDD-1609’s likelihood of approval (LoA) and phase transition for Pruritus took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RDD-1609 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

RDD-1609 overview

RDD-1609 is under development for the treatment of pruritus ani (anusitis). The drug candidate is administered through rectal route. It is a new therapeutic entity of known/approved molecules with established safety and toxicology profiles. It is developed based on capository technology.

9 Meters Biopharma overview

9 Meters Biopharma, formerly Innovate Biopharmaceuticals Inc, is a clinical-stage biopharmaceutical company developing novel medicines for autoimmune and inflammatory diseases. The company’s pipeline products include NM-002, long-acting injectable GLP-1 analogue for short bowel syndrome (SBS); Larazotide, orally administered, gut-restricted tight-junction regulator for celiac disease; NM-003, long-acting GLP-2 analogue, under orphan indication selection; and NM-004, immunomodulator, granted pediatric orphan designation in ulcerative colitis. 9 Meters Biopharma is headquartered in Raleigh, North Carolina, the US.

Quick View RDD-1609 LOA Data

Report Segments
  • Innovator
Drug Name
  • RDD-1609
Administration Pathway
  • Rectal
Therapeutic Areas
  • Dermatology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.